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Background Fever, hyperglycemia, and swallow dysfunction
poststroke are associated with significantly worse outcomes.
We report treatment and monitoring practices for these three
items from a cohort of acute stroke patients prior to random-
ization in the Quality in Acute Stroke Care trial.
Method Retrospective medical record audits were undertaken
for prospective patients from 19 stroke units. For the first
three-days following stroke, we recorded all temperature
readings and administration of paracetamol for fever (≥37·5°C)
and all glucose readings and administration of insulin for
hyperglycemia (>11 mmol/L). We also recorded swallow
screening and assessment during the first 24 h of admission.
Results Data for 718 (98%) patients were available; 138 (19%)
had four hourly or more temperature readings and 204
patients (29%) had a fever, with 44 (22%) receiving paraceta-
mol. A quarter of patients (n = 102/412, 25%) had six hourly or
more glucose readings and 23% (95/412) had hyperglycemia,
with 31% (29/95) of these treated with insulin. The majority of
patients received a swallow assessment (n = 562, 78%) by a
speech pathologist in the first instance rather than a swallow
screen by a nonspeech pathologist (n = 156, 22%). Of those
who passed a screen (n = 108 of 156, 69%), 68% (n = 73) were
reassessed by a speech pathologist and 97% (n = 71) were
reconfirmed to be able to swallow safely.
Conclusions Our results showed that acute stroke patients
were: undermonitored and undertreated for fever and hyper-
glycemia; and underscreened for swallowing dysfunction and
unnecessarily reassessed by a speech pathologist, indicating
the need for urgent behavior change.
Key words: fever, hyperglycemia, insulin, paracetamol, stroke, swallow
screen
Introduction
In the first few days of an acute stroke, fever occurs in 12–50%
of patients (1–4), hyperglycemia occurs in more than 40% of
patients (5,6), and swallowing dysfunction occurs in 37–78% of
patients (7). All three variables in the early poststroke period are
associated with a significant increase in morbidity and mortality
(8–10) (7,11). The administration of paracetamol has been found
to be an effective therapy in reducing fever among patients with
stroke (12) as has the treatment of hyperglycemia with insulin
following acute stroke in reducing glucose levels (13). However,
there is currently no clinical evidence that tight glycemic control
during the acute stroke phase improves outcomes (13). Studies
have shown that nonspeech pathologists can safely perform swal-
lowing screening before a speech pathologist comprehensive
assessment for those who fail the screen (14–16) and the use of a
formal dysphagia screening protocol has been associated with
improved compliance with dysphagia screening and a signifi-
cantly reduced risk of pneumonia (17).
To ensure optimum outcomes for stroke patients, early detec-
tion and treatment of fever, hyperglycemia, and swallowing dys-
function following acute stroke should be a priority (18).
International guidelines from the United Kingdom (19), United
States (20), Europe (21), Canada (22), and Australia (23) (Box 1)
recommend similar monitoring and treatment practices for the
management of fever, hyperglycemia, and swallowing; however,
these recommendations are generally nonspecific, that is, only the
Canadian guidelines included a recommendation specific to
the frequency of temperature monitoring within the first 48 h
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following admission for acute stroke (every four-hours) (22).
Four of these five guidelines recommended that paracetamol be
used routinely to treat fever (18,20–23), but only two provided a
threshold for treatment (>37·5°C) (21,22). No guidelines
included recommendations specific to the frequency of glucose
monitoring following stroke diagnosis and insulin was recom-
mended for treatment of hyperglycemia in three of the five guide-
lines (20,22,23), with only two providing a threshold for
treatment [maintain between 4 and 11 mmol/l; lower glucose
levels to 300 mg/dl (16·7 mmol/l)] (Box 1) (19,20). For the man-
agement of swallowing dysfunction following acute stroke, of the
five guidelines reviewed, three recommended a swallow screen (by
nonspeech pathologist) be undertaken within the first 24 h of
admission to the hospital and prior to being given food, drink, or
oral medications (19,22,23). Two of the three guidelines recom-
mending a swallow screen also recommended a comprehensive
swallow assessment (by speech pathologist) for those with a failed
screen (19,23). One of the guidelines recommended a swallow
assessment but no swallow screen (21). One guideline failed to
include any recommendation pertaining to the management of
swallowing dysfunction (20).
The Quality in Acute Stroke Care Trial (QASC) (24,25), a
cluster randomized controlled trial, was designed to test the effect
of a multidisciplinary team building intervention to implement
evidence-based treatment protocols for the management of fever,
hyperglycemia, and swallowing dysfunction on 90-day poststroke
outcomes and clinician behavior change. Panels of experts devel-
oped three clinical treatment protocols using recommendations
Box 1 International guideline recommendations for fever, hyperglycemia, and swallowing dysfunction^
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^ As published at time of QASC intervention implementation period (May 2007 to Aug 2010).
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from Australia’s national clinical guidelines for stroke (23). The
protocols included specific monitoring and treatment targets for
fever, hyperglycemia, and swallowing dysfunction (Box 2). Our
monitoring and treatment target for fever (37·5 C) was consistent
with international guideline recommendations (19,21,22). With
regard to glucose monitoring, our protocol recommended six
hourly monitoring when nonhyperglycemic, with more frequent
monitoring only when the glucose was elevated. Nurses have a
duty of care to monitor patients, particularly in the acute phase,
and these frequencies seem an appropriate minimum in the
absence of data. We acknowledge the lack of evidence for tight
glycemic control, hence our protocols did not support this.
Instead, we aimed to treat major episodes of hyperglycemia in
accordance with guideline recommendations (18,23). Similarly,
our monitoring and treatment targets for swallowing dysfunction
following acute stroke were consistent with our national stroke
guidelines published prior to and after the commencement of the
QASC trial (18,23). To date, it is unknown what effect compre-
hensive and standardized management protocols for these three
variables would have on patient management and outcomes.
Prior to randomization and implementation of the protocols
within the QASC trial, we aimed to establish baseline practices for
the monitoring and treatment of fever (temperature ≥ 37·5°C);
hyperglycemia (glucose level >11 mmol/l), and swallowing dys-
function. This was also a unique opportunity to investigate clini-
cian adherence with recommendations pertaining to the
management of fever, hyperglycemia, and swallowing dysfunction
following acute stroke from the Australian Clinical Guidelines for
Acute Stroke Management (18).
Method
Retrospective medical record audits were undertaken from
January to November 2009 of patients prospectively recruited
between July 2005 and October 2007 (for the preintervention
cohort of the QASC trial).
Participants
Nineteen hospitals in New South Wales (NSW), Australia that had
Categories A and B acute stroke units (those that had immediate
access to brain imaging and high dependency units) (26) were
eligible to participate. Eligible patients were those admitted to
these stroke units within 48 h of developing stroke symptoms;
were diagnosed with an ischemic stroke or intracerebral hemor-
rhage; were greater than 18 years of age; spoke English; and had
access to a telephone. Patients who died while in hospital were still
included in the audit if they met the eligibility criteria and were
managed in a participating stroke unit. Patients who were diag-
nosed with severe stroke and referred for palliation were excluded
from the study.
Outcome measures
All outcomes were derived from the protocols (Box 2) and were
measured at the individual or event level (Tables 2, 3 and 4 and 5).
Data collection
Four auditors, not otherwise involved in the QASC trial and blind
to the study design, collected the audit data as follows: all tem-
perature readings and administration of paracetamol for fever
(≥37·5°C) over the first 72 h of admission to the stroke unit; all
finger-prick glucose readings and administration of insulin for
hyperglycemia (>11 mmol/L) over the first 72 h of admission to
the stroke unit; venous blood glucose levels in the emergency
department or within two-hours of stroke unit admission; and
swallowing surveillance including swallowing screens by non-
speech pathologists and comprehensive swallowing assessments
by speech pathologists within the first 24 h of hospital admission.
To meet the criteria for a successful swallowing screening, all the
three following individual elements had to be documented: level
of consciousness, cranial nerve assessment (specifically cranial
nerves IX, X and XI), and a water swallow test. Alternatively, a
hospital approved swallowing screen tool (with these three com-
ponents) had to be completed. In our participating hospitals, and
common practice within NSW at this time, speech pathologists
Box 2 QASC trial clinical treatment protocols (also referred to as FeSS [fever, sugar, swallow] protocols)*
Fever
1. Temperature monitored and charted four hourly for 72 h following stroke unit admission.
2. Temperature ≥37·5°C treated with paracetamol (IV, PR, or oral).
Sugar (hyperglycemia)
1. Venous blood glucose measured (venous blood not finger prick) on admission to hospital.
2. At least six hourly finger-prick blood glucose readings for 72 h following stroke unit admission.
3. On admission to stroke unit, if blood glucose level:
>11 mmol/l and known diabetic, commence insulin (IV or SC).
>16 mmol/l and patient without known diabetes, commence insulin (IV or SC).
4. If blood glucose level >11 mmol/l at any time in first 72 h following stroke unit admission, commence insulin.
Swallowing dysfunction
1. Swallow screen within 24 h of stroke unit admission if not attended in the emergency department.
2. Patients who fail the swallow screen refer to a speech pathologist for a swallowing assessment.
Key:
IV, intravenous; PR: per rectum; QASC, Quality in Acute Stroke Care Trial; SC, subcutaneous.
*Further information about the QASC trial including the treatment protocols and QASC medical record audit tool is available at
http://www.acu.edu.au/qasc
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perform a full swallow assessment when called to see patients;
swallow screens were performed only by nonspeech pathologists.
Auditors also collected information on: age, gender, stroke sub-
type (Oxfordshire Community Stroke Project classification) (27);
stroke severity [Scandinavian Stroke Scale (SSS)] (28); level of
disability on admission (modified Rankin Scale [mRS]) (29); date
and time of symptom onset; date and time of admission to the
emergency department (where relevant); date and time of admis-
sion to the stroke unit; hospital discharge date; death during
hospitalization; and diabetic status. The QASC audit tool and data
dictionary are accessible via http://www.acu.edu.au/qasc.
Auditors attended a two-day training program. Audits were
conducted by two pairs of auditors who undertook dual indepen-
dent data abstraction, enabling clarification of uncertainties.
For quality assurance purposes, 10% of patient records were
re-audited.
This study was approved by the Human Research Ethics Com-
mittee of the Australian Catholic University and the relevant
Human Research Ethics Committees of all participating hospitals.
Data analysis
Analyses were undertaken using STATA 11·0 software (StataCorp,
Blackburn North, Victoria, Australia). Frequency distributions of
socio-demographic and clinical characteristics of the sample are
presented. Because patients who experience fever and hypergly-
cemia had an increased number of readings recorded, we com-
puted a mean temperature and blood glucose reading for each
patient for the first 72 h following stroke unit admission, and
using these, then determined the sample mean temperature and
glucose level (i.e., mean of the patient mean values). Because
paracetamol can only be administered 4–6 hourly within 24 h
(30), the analysis was restricted to treatment of the first febrile
event only. The number and proportion of patients with each
outcome (for binary measures), means and standard deviations
for normally distributed continuous variables or medians and
quartiles for nonnormally distributed continuous variables are
presented with 95% confidence intervals (CIs), with exact CIs
obtained for medians using the binomial method (31). Compari-
sons for hyperglycemic management between patients with dia-
betes and patients without a history of diabetes were carried out
using the Wald chi-square test adjusted for clustering by hospital.
Results
Of the 735 eligible QASC consenting patients, 17 medical records
were unable to be located and 718 (98%) patients had their data
audited (missing data 2·3%).
Almost half of the patients (n = 307 of 630; 49%) were aged 75
or above and over half (n = 403, 57%) were male. Thirty-nine
percent of patients (n = 218 of 558) had a Partial Anterior Circu-
lation Infarct (32). The majority of patients had an SSS of >30
[n = 427 (84%) of 506], indicating a mild to moderate stroke (28),
and just under half the patients had an admission mRS ≥ 2
[n = 330 (49%) of 674] which indicated some degree of depen-
dency or death. Eight patients (1%) died while in hospital. Most
patients (n = 640, 89%) were admitted to the stroke unit via the
emergency department, and the median time spent in the emer-
gency department prior to transfer to the stroke unit was 7·4 h
(n = 640) (Q1 5·7, Q3 10·1). The median hospital length of stay
was 8 days (Q1 6, Q3 12) (Table 1).
Management of fever
Temperature was recorded at least once within 72 h of stroke unit
admission for 714 patients (99%), of whom 138 (19%, 95% CI
16–22%) had one or more temperature readings every four-
hours. The mean temperature reading within the first 72 h of
admission to the stroke unit was 36·6°C (SD 0·30). During this
period, 204 patients (29%, 95% CI 25–32%) had a temperature
reading ≥ 37·5°C, of whom 44 (22%, 95% CI 16–27%) received
paracetamol within two-hours of the first febrile event. The
median time to administration of paracetamol [for those where
time of temperature reading and/or paracetamol administration
time was documented (n = 41) for the first instance of fever
(≥37·5°C)] was 30 min (Q1 10, Q3 120 min) (Table 2).
Table 1 Demographic and clinical characteristics*,†
n %





Gender (n = 712)
Male 403 57
Female 309 43
Mortality status (n = 718)
Survived 710 99
Died while in hospital 8 1
Admission to stroke unit via (n = 718)
Emergency department 640 89
Other 78 11
Oxfordshire Community Stroke Project (n = 558)
Partial anterior circulation infarct 218 39
Lacunar infarct 141 25
Posterior circulation infarct 81 15
Total anterior circulation infarct 49 9
Intracerebral hemorrhage 39 7
Trans ischemic attack 30 5
Scandinavian Stroke Score (n = 506)
0–14 (Very severe) 34 7
15–29 (Severe) 45 9
30–44 (Moderate) 126 25
45–58 (Mild) 301 59
Modified Rankin Score documented in the
emergency department or within 72 h of
stroke unit admission (n = 674)
0 – No symptoms at all 108 16
1 – No significant disability despite symptoms 236 35
2 – Slight disability 103 15
3 – Moderate disability 106 16
4 – Moderately severe disability 30 4
5 – Severe disability 48 7
6 – Dead 43 6
*Percents may not total to 100%, due to rounding.
†Denominators vary due to missing data.
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Management of hyperglycemia
Just over one quarter of the patients (n = 186, 26%, 95% CI
23–29%) had a formal venous blood glucose (nonfinger-prick)
measured in the emergency department or within two-hours of
stroke unit admission. The mean formal venous blood glucose
measurement taken in the emergency department or within two-
hours of stroke unit admission was 6·4 (SD 2·6). A finger-prick
glucose reading was recorded at least once within the first 72 h of
stroke unit admission for 412 (57%) patients, of whom 158 (38%,
95% CI 34–43%) had a finger-prick glucose reading recorded
within two-hours of stroke unit admission and 102 patients
(25%, 95% CI 21–29%) had at least one or more finger-prick
glucose readings every six-hours. The mean finger-prick glucose
reading for those who had had at least one finger-prick glucose
reading (n = 412) was 7·1 mmol/l (SD 2·0). Ninety-five of the 412
patients (23%, 95% CI 19–27%) had a finger-prick glucose
reading >11 mmols/l. Twenty-nine (31%, 95% CI 21–40%) of
these hyperglycemic patients were treated with insulin, with the
median time to treatment of first hyperglycemic episode being
11 min (Q1 0, Q3 26 min) (Table 3).
A history of diabetes was documented for 115 patients (16%).
Patients with known diabetes (n = 115) were significantly more
likely when compared with patients without known diabetes to
receive: a venous blood glucose in the emergency department or
within two-hours of stroke unit admission (39% versus 23%,
P = 0·002); a finger-prick glucose reading at any time within the
first 72 h of stroke unit admission (94% versus 50%, P = < 0·001);
at least one finger-prick glucose reading within two-hours of
Table 2 Fever processes of care measures
Outcome Eligible sample n (%) 95% CI
Monitoring
Patients with at least one temperature reading recorded every four-hours or
more within the first 72 h of stroke unit admission
714 138 (19%) 16% to 22%
Mean temperature reading within first 72 h of stroke unit admission (°C) (for
those who had at least one temperature reading)
714 36·63 (0·30)* 36·61 to 36·65
Patients with a febrile event (temperature ≥37·5°C) within the first 72 h of stroke
unit admission (for those who had at least one temperature reading)
714 204 (29%) 25% to 32%
Treatment
Patients administered paracetamol within two-hours when temperature ≥37·5°C
(at first febrile event)
204 44 (22%) 16% to 27%
Time (minutes) to administration of paracetamol when temperature ≥37·5°C at
first febrile event (for those who received paracetemol)
41 of 44‡ 30 (10, 120)† 57 to 314
*Mean of means (SD).
†Median (Q1, Q3).
‡Data are missing.
Table 3 Hyperglycemia processes of care measures
Outcome Eligible sample n (%) 95% CI
Monitoring
Patients with a formal venous glucose measurement in the emergency department or within
two-hours of stroke unit admission
718 186 (26%) 23% to 29%
Mean formal venous glucose measurement taken in the emergency department or within
two-hours of stroke unit admission
186 6·4 (SD 2·6) 6·1 to 6·6
Patients with at least one finger-prick glucose reading taken within the first 72 h of stroke unit
admission
718 412 (57%) 54% to 61%
Patients with finger-prick glucose reading recorded within two-hours of stroke unit admission
(for those who had at least one finger-prick glucose reading)
412 158 (38%) 34% to 43%
Patients with at least one finger-prick blood glucose reading recorded every six-hours within
72 h of stroke unit admission (for those who had at least one finger-prick glucose reading)
412 102 (25%) 21% to 29%
Mean finger-prick glucose reading recorded within 72 h of stroke unit admission (mmol/l) (for
those who had at least one finger-prick glucose reading)
412 7·1 (2·0)* 6·9 to 7·3
Patients with a hyperglycemic event (finger-prick blood glucose >11 mmol/l) within 72 h of
stroke unit admission (for those who had at least one finger-prick glucose-reading)
412 95 (23%) 19% to 27%
Treatment
Patients treated with insulin when finger-prick blood glucose >11 mmol/l 95 29 (31%) 21% to 40%
Time (mins) to administration of insulin when first finger-prick blood glucose >11 mmol/l (for
those administered insulin)
9 of 29‡ 11 (0, 26)† −20 to 109
*Mean of means (SD).
†Median (Q1, Q3).
‡Data are missing.
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stroke unit admission (50% versus 34%, P = 0·002); at least one or
more finger-prick glucose readings sixth hourly within the first
72 h of stroke unit admission (70% versus 9%, P = < 0·001); and
be treated with insulin when finger-prick glucose reading
>11 mmols/l (36% versus 16%, P = 0·01) (Table 4).
Among patients with known diabetes, 26 (23%) had a finger-
prick reading >11 mmols/l within the first two-hours of stroke
unit admission (first finger-prick), and of these, 11 patients (42%)
were administered insulin. Among patients without known dia-
betes, only one had a finger-prick reading >16 mmols/l on admis-
sion to the stroke unit. This patient was not treated with insulin
(Table 4).
Management of swallowing dysfunction
The majority of patients (n = 662, 92%, 95% CI 90–94%) under-
went swallowing surveillance either in the form of a swallow
screen by a nonspeech pathologist (n = 156, 22%) or swallow
assessment by a speech pathologist (n = 506, 78%) within 24 h of
hospital admission. The majority of screens (n = 149, 96%, 95%
CI 92–99%) were conducted in the emergency department and
only seven (7) screens (4%, CI 1–9%) were conducted in the
stroke unit (Table 5).
Of those patients who underwent a screening by a nonspeech
pathologist within 24 h of admission (n = 156, 22%), 48 patients
(31%, 95% CI 23–38%) were deemed to have an unsafe swallow,
of whom 47 (98%) were then reviewed by a speech pathologist
and underwent a swallow assessment. Of those who were seen by
the speech pathologist and had an assessment, nine (19%, 95% CI
7–31%) were deemed to have dysphagia. The median time
between failing a swallow screen (by nonspeech pathologist) and
a swallow assessment by a speech pathologist was 23·3 h (Q1
5·7 h, Q3 47·6 h) (Table 5).
An analysis to determine if patients who had passed a screen
and were then further unnecessarily assessed by a speech patholo-
gist showed that of the 108 patients (69%) who passed the swal-
lowing screen, 73 (68%) had a full assessment subsequently
performed by a speech pathologist. Of those who were
re-assessed, 97% (n = 71, 95% CI 93–99%) were deemed by the
speech pathologist to have a safe swallow.
Discussion
The aim of our study was to investigate current management
practices for fever, hyperglycemia, and swallowing dysfunction
following stroke. We acknowledge that there is a lack of data to
support tight monitoring and treatment of fever and hyperglyce-
mia in the acute phase following stroke. However, we argue that
nurses have a duty of care to monitor patients regularly, particu-
larly in the acute phase, and treat according to best evidence. Four
hourly temperature monitoring for the first 72 h, as stipulated in
our protocol, is consistent with international guideline recom-
mendations (22). Furthermore, it also allows for early identifica-
tion of fever from other causes such as infection (i.e., aspiration
pneumonia). With regard to glucose monitoring, our protocol
recommended six hourly monitoring when nonhyperglycemic,
with more frequent monitoring only when the glucose was
elevated. Again, these frequencies seem an appropriate minimum
in the absence of data. Our results indicate that the monitoring
and treatment for fever and hyperglycemia in NSW stroke units
were suboptimal. Although our national stroke guidelines recom-
mend that all stroke patients be screened for swallowing dysfunc-
tion, clinician adherence with these guideline recommendations
is poor and urgent behavior change is required.
Table 4 Hyperglycemia processes of care measures among patients with known diabetes and patients without known diabetes
Outcome
Patients with known
diabetes n = 115
Patients without known
diabetes n = 603
P*
Difference between
groups (95% CI)†n (%) n (%)
Monitoring
Patients with a formal venous glucose measurement in the
emergency department or within two-hours of stroke unit
admission
45 (39) 141 (23) 0·002 15% (6% to 24%)
Patients with at least one finger-prick glucose reading taken
within the first 72 h of stroke unit admission
108 (94) 304 (50) <0·001 40% (33% to 48%)
Patients with finger-prick glucose reading recorded within
two-hours of stroke unit admission (for those who had at
least one finger-prick glucose reading)
54 of 108 (50) 104 of 304 (34) 0·002 17% (6% to 28%)
Patients with at least one finger-prick blood glucose reading
recorded every six-hours within 72 h of stroke unit admission
(for those who had at least one finger-prick glucose reading)
76 of 108 (70) 26 of 304 (9·0) <0·001 62% (53% to 71%)
Patients with at least one finger-prick blood glucose reading
>11 mmol/l (for those who had at least one finger-prick
glucose reading)
70 of 108 (65) 25 of 304 (8) <0·001 50% (47% to 66%)
Treatment
Patients treated with insulin when finger-prick blood glucose
>11 mmol/l (for those who had at least one finger-prick
glucose reading)
25 of 70 (36) 4 of 25 (16) 0·01 23% (5% to 40%)
*P values are from Wald chi-square test.
†Adjusted for clustering of patients within stroke units; thus, is not necessarily equal to the absolute difference in percentages between groups.
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Management of fever
Fever occurred in approximately one third of patients which is
consistent with prior studies that have defined fever as ≥37·5°C
(3,33). Comparisons with other studies are difficult because of
differences in fever definition. In our study, only 19% of patients
had at least one temperature reading recorded four hourly within
the first 72 h following stroke unit admission. Furthermore, poor
fever management practices were noted, with only 22% of
patients with fever treated with paracetamol at their first febrile
event. A failure to monitor patients and treat temperature is of
concern, considering that fever has been associated with poor
outcomes following stroke (8,33–36), and that paracetamol has
been found to be an effective therapy in reducing fever among
patients with stroke (12,37).
Little is known about which individual aspects of fever, that is,
level of fever or duration, are associated with poor outcomes
(38,39). Although the administration of paracetamol was timely
(median 30 min), further studies exploring temperature duration
and associated outcomes are required. This is one of the first
studies reporting how quickly fever is treated in acute stroke
patients.
Management of hyperglycemia
Only 23% of stroke patients, who had a finger-prick glucose mea-
surement within the first 72 h of stroke unit admission, experi-
enced a hyperglycemic event (finger-prick glucose >11 mmol/l)
which is lower than the 43–68% previously reported (9). This may
be attributed to our definition of hyperglycemia (finger-prick
glucose >11 mmol/l), which is higher than that reported in prior
studies (6·1–10 mmol/l) (9).
Despite guidelines recommending glucose testing following
stroke, 74% of acute stroke patients in our study did not have a
venous blood glucose measured in the emergency department or
within two-hours of stroke unit admission. During the first 72 h
of stroke unit admission, 43% of acute stroke patients had no
finger-prick glucose monitoring. Of those who had their finger-
prick glucose monitored (n = 412, 57%), only 25% had at least
one finger-prick glucose level recorded every six-hours. A failure
to monitor the patient’s glucose levels frequently, or at all, may
result in hyperglycemia being undetected, despite the association
of hyperglycemia in the early poststroke period with worse out-
comes (9,10). Patients without known diabetes were less likely to
have a venous blood glucose measurement, nor finger-prick
glucose monitoring at any time in the first 72 h of stroke unit
admission compared with patients with known diabetes, but even
among those with known diabetes, the level of testing was
extremely poor. Furthermore, patients without known diabetes
were also less likely to have hyperglycemic events treated with
insulin. This is of concern, considering that stroke patients
without known diabetes who have even moderately elevated
glucose levels (>6·7 to 8 mmol/l) on admission have a threefold
risk of death relative to known diabetic patients with this same
level of elevated glucose (9).
Our findings indicate suboptimal treatment of hyperglycemia
following acute stroke which has also been reported in prior
studies (40). In our study, only 31% of patients received corrective
treatment for a hyperglycemic event (finger-prick glucose
>11 mmol/l) with insulin, and it is clear that more effort to opti-
mize glucose control is needed. Clinicians failed to recognize that
hyperglycemia is a significant event in stroke regardless of diabe-
tes status.
Management of swallowing dysfunction
The majority of patients (92%) in our cohort underwent
swallowing surveillance within 24 h of hospital admission.
Although international guidelines recommend that patients only
receive a swallow assessment following a failed screen (19,23),
our results indicate that the majority of patients received a com-
prehensive speech pathologist assessment (78%) and no swallow
screen.
Table 5 Swallowing dysfunction processes of care measures
Outcome Eligible sample n (%) 95% CI
Monitoring
Patients who underwent swallow surveillance in the form of a swallow screen and/or
swallow assessment within 24 h of hospital admission
718 662 (92) 90% to 94%
Patients who underwent a swallow screen (by nonspeech pathologist) in the emergency
department or within 24 h of stroke unit admission
718 156 (22) 19% to 25%
Patients who underwent a swallow screen (by nonspeech pathologist) in the emergency
department (for those who had a swallow screen)
156 149 (96) 92% to 99%
Patients who underwent a swallow screen (by nonspeech pathologist) in the stroke unit
and within 24 h of stroke unit admission (for those who had a swallow screen)
156 7 (4) 1% to 9%
Suspected dysphagia (for those who had a swallow screen by nonspeech pathologist 156 48 (31) 23% to 38%
Treatment
Proportion who underwent a speech pathologist assessment following suspected
dysphagia (for those who had failed the swallow screen undertaken by nonspeech
pathologist)
48 47 (98) 94% to 100%
Deemed to have an unsafe swallow by speech pathologist and placed nil by mouth 47 9 (19) 7% to 31%
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That 68% of patients who had passed a swallow screen subse-
quently also received a full speech assessment by a speech
pathologist is of note. It is possible that this additional surveil-
lance may have been unnecessary because 97% of patients initially
screened by a nonspeech pathologist and passed were also deemed
to have a safe swallow following an assessment by the speech
pathologist. However, we acknowledge the small, but unlikely,
possibility that all of these patients deteriorated and required a
subsequent speech pathologist consultation.
The majority of screens were conducted in the emergency
department (96%) rather than in the stroke unit (4%). We did not
investigate whether a patient received food, fluids, or medications
prior to a screen; and if a patient had received food, fluids, or
medications in the emergency department, this may have been a
deterrent for any further screening in the stroke unit as stroke unit
nurses may have assumed the patient had previously been deemed
to have a safe swallow. Further exploration of administration of
food, fluids, or medications before swallowing screen or assess-
ment is warranted.
Our results also indicated that a patient who failed a screen by
a nonspeech pathologist was required to wait nearly 24 h nil by
mouth before undergoing a speech pathologist assessment.
Further studies exploring contributions to lengthy waiting times
for a speech pathologist assessment are required.
Our study was limited to the investigation of the monitoring
and treatment for fever, hyperglycemia, and swallowing dysfunc-
tion in the first 72 h of stroke unit admission. Other studies have
examined these parameters up to seven-days (35,41); however, the
majority of febrile episodes (58%) have been found to occur in
the first 72 h of admission (39). Data were not collected on the
route of the temperature measurement because this was rarely
documented. We were unable to identify from the medical records
whether nonspeech pathologist personnel who undertook the
swallow screenings were specifically trained in swallowing screen-
ing or whether any screening tools used had been validated.
However, we acknowledge the following strengths of our study.
We included a large cohort of patients from 19 stroke units, thus
enhancing generalizability; we also recorded all temperature and
hyperglycemic measurements, thus we have complete data on the
etiology of fever and hyperglycemic events within the first 72 h
following a stroke.
In conclusion, the management of fever, hyperglycemia, and
swallowing dysfunction in the acute phase following stroke was
suboptimal, indicating the need for urgent behavior change. Our
review of international guideline recommendations pertaining to
the management of fever, hyperglycemia, and swallowing dys-
function highlighted that standardized recommendations for the
monitoring and treatment of fever, hyperglycemia, and swallow-
ing dysfunction following acute stroke do not exist. The QASC
trial (24) has developed evidence-based protocols with specific
monitoring and treatment targets for these three physiological
variables. Prior studies have identified that the distribution alone
of guidelines and protocols will not change clinician behavior
(42), thus further research is required to identify effective behav-
ior change interventions to promote the uptake of guideline and
protocol recommendations. Our data provide preintervention
processes of care measures to determine the effect of our stan-
dardized protocols for the management of fever, hyperglycemia,
and swallowing dysfunction following acute stroke on clinician
behavior change and ultimately patient outcomes.
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